Fluorescein circulation time and the treatment of hypertension in the aged.
D000328:Adult; D000367:Age Factors; D000368:Aged; D001776:Blood Circulation Time; D001794:Blood Pressure / Q000187:drug effects; D002219:Carbamates / Q000627:therapeutic use; D004976:Ethacrynic Acid / Q000627:therapeutic use; D005260:Female; D005452:Fluoresceins; D005665:Furosemide / Q000627:therapeutic use; D005919:Glomerular Filtration Rate; D006145:Guanethidine / Q000627:therapeutic use; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D007676:Kidney Failure, Chronic / Q000150:complications; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D011188:Potassium / Q000627:therapeutic use; D012110:Reserpine / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use
D002219:Carbamates; D005452:Fluoresceins; D006852:Hydrochlorothiazide; D006830:Hydralazine; D013148:Spironolactone; D008750:Methyldopa; D005665:Furosemide; D012110:Reserpine; D004976:Ethacrynic Acid; D011188:Potassium; D006145:Guanethidine